The progress made in liver disease research to date presents an opportunity for further advancements in the near future.

Announced Positive Clinical Data for Adult and Pediatric Netherton Patients ASHBURN, Va., May 13, 2025 (GLOBE NEWSWIRE) -- ...

The chronic pruritus market is expected to grow across the 7MM, driven by the introduction of innovative therapies like ...

The phase 3 GLISTEN trial has been evaluating the candidate in adults with PBC and cholestatic pruritus, or relentless itch, ...

Updated GLISTEN trial results presented at EASL 2025 confirm that the IBAT inhibitor linerixibat significantly improved worst ...

Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid itch ...

Seventy percent of patients treated with volixibat experienced a ≥50% reduction in serum bile acids - Volixibat treated ...

The GLISTEN trial of GSK's linerixibat has shown that the oral ileal bile acid transporter (IBAT inhibitor was signposted as ...

Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical ...

GSK has reported positive outcomes from the randomised Phase III GLISTEN trial of the targeted inhibitor of ileal bile acid ...

More patients in the linerixibat group had clinically meaningful itch improvement (WI-NRS =3-point reduction) with 56% versus 43% in the placebo group at week 24 (treatment difference 13% [95% CI ...

Linerixibat, an investigational oral ileal bile acid transporter (IBAT) inhibitor, improved cholestatic pruritus in patients ...